ClinicalTrials.gg
Not yet recruitingNCT06645171BISONUpdated Oct 16, 2024

Effect of an Oral Nutritional Supplement (ONS) with Prebiotic Fibre Compared to a Non-fibre Containing ONS Equal in Energy and Protein Content on Gut Microbiota in Older Adults with or At Risk of Disease Related Malnutrition

An interventional study of Fibre drink in Changes in Gut Microbiota Bifidobacterial Levels, sponsored by Nutricia Research. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Nutricia Research (part of Danone) · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This study assesses the effects of an oral nutritional supplement (ONS) with fibre compared to a non-fibre containing ONS equal in energy and protein content on gut microbiota bifidobacteria in older adults with or at risk of disease related malnutrition. It is a randomised controlled, double blind, parallel-group, multi-country study. Subjects will receive an ONS with or without (control group) fibre. They take it twice a day for 4 weeks and the change in their gut microbiota bifidobacterial levels is the primary outcome. They will be measured at day 1 (V1), day 15 (V2) and week 4 (V3).

02

Conditions studied

  • Changes in Gut Microbiota Bifidobacterial Levels
03

In context

Lead sponsor

Nutricia Research is the lead sponsor of 51 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. 65 years of age or older 2. Identified as at medium or high risk of malnutrition based on:

      a) MNA-SF score between 0 - 11 and / or b) are prescribed with ONS 3. In need of 2 servings of oral nutritional support/day (300 kcal; 12 gr protein per serving).

      1. a) Not being prescribed with ONS or b) being prescribed with non-fibre containing ONS and willing and able to switch from pre-study prescribed ONS to the Test or Control Product for participation in the study.
      1. Willing to maintain dietary habits for the duration of the study. Written from subject (or impartial witness after verbal consent of subject when subject is physically unable to sign and where allowed by local regulations).

Exclusion criteria

Exclusion Criteria:

    1. Requirement for a fibre-free diet. 2. Have used nutritional supplements with fibre/prebiotics and/or probiotics content at any point during 3 weeks prior to start study (Visit 1) and / or will not refrain from using these kinds of products during the study period.

      1. Admitted to an intensive care unit. 4. Hemodynamically unstable. 5. Known allergy to cow's milk protein. 6. Known galactosaemia. 7. Known hepatic encephalopathy. 8. Known Irritable Bowel Syndrome. 9. Known severe lactose intolerance without using lactase. 10. Known history of GI surgery. 11. Known history of intestinal polyp removal within 3 months prior to the study.
      1. Known history of Immunotherapy. 13. Known history of GI cancer. 14. Active cancer treatment or within 12 months prior the study 15. Diagnose of Celiac Disease. 16. Received antibiotics within 4 weeks prior to study. 17. Patients following a vegan or vegetarian diet. 18. Active flare of inflammatory bowel disease as defined by HBI >6 (Crohn's disease) or SCCAI >5 (ulcerative colitis).
      1. Stricturing Crohn's disease. 20. Any to oral feeding per se being: gastrointestinal failure or suppressed gastrointestinal function, complete intestinal obstruction and major intra-abdominal sepsis.
      1. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements, for example due to the presence of a psychiatric disorder (e.g. major depression, psychoses), dementia or Alzheimer's disease.
      1. Planned hospital admission during the study period in case not hospitalised at screening 23. Participation in any other studies involving or marketed products concomitantly or within 6 weeks prior to baseline.
      1. Severe disease with less than a year.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Arm 1

    ONS including fibre (300 kcal, 12gr protein, 125 mL, 4.5 g fibre), The subjects will use study products twice daily for 4 weeks starting at V1.

    Dietary Supplement: Fibre drink

  • Experimental
    Arm 2

    ONS without fibre (300 kcal, 12gr protein, 125 mL, 0 g fibre), The subjects will use control products twice daily for 4 weeks starting at V1.

    Dietary Supplement: Fibre drink

Interventions

  • Dietary supplementFibre drink

    One drink will be tested

06

What researchers measure

Primary outcomes

  1. Changes in gut microbiota bifidobacterial levels

    Time frame: 4 weeks

Secondary outcomes

  1. Changes in gut microbiota composition

    Time frame: 4 weeks

  2. Fecal pH

    Time frame: 4 weeks

  3. Stool frequency and consistency assessed by the Bristol Stool Form Scale (BSFS)

    Time frame: 4 weeks

  4. Total short-chain fatty acids (SCFA)

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Dec 2026, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 16, 2024
StartEst.
Nov 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06645171
Lead sponsor
Nutricia Research
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Nov 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 16, 2024

Study contacts

Danone Global Research & Innovation Center
Contact
register.clinicalresearchnutricia@danone.com
+31 30 2095 000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion